CI

At a glance

ClinicalIndex Comparison Record
N/AUnknown· 25,871 enrolled
Drug / intervention
Omega-3 fatty acids (fish oil) +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01782352
NCT01782352N/AUnknown

Age-related Macular Degeneration (AMD) in the Vitamin D and Omega-3 Trial (VITAL)

Brigham and Women's Hospital·interventional·Posted Feb 1, 2013·Updated Aug 8, 2023

In Brief

A clinical study evaluating Omega-3 fatty acids (fish oil), Vitamin D3, and 2 other interventions for Age-related Macular Degeneration. Targeting 25,871 participants across 1 site.

Detailed Summary

The VITamin D and OmegA-3 Trial (VITAL; NCT 01169259) is a randomized clinical trial in 25,875 U.S. men and women investigating whether taking daily dietary supplements of vitamin D3 (2000 IU) or omega-3 fatty acids (Omacor fish oil, 1 gram) reduces the risk of developing cancer, heart disease, and stroke in people who do not have a prior history of these illnesses. This ancillary study is being conducted among participants in VITAL and will examine whether vitamin D or omega-3 fatty acids, compared to placebo, reduce the incidence and/or progression of age-related macular degeneration (AMD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

N/AUnknownOverdue
2011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 1, 2013
Enrollment StartJul 1, 2010
Primary CompletionDec 1, 2019
Study CompletionSep 1, 2024
TodayJul 2, 2026
Enrollment to primary: 9.4 yearsPosted 13.4 years ago

Interventions

Omega-3 fatty acids (fish oil)drug

Vitamin D3dietary

Vitamin D3 placebodietary

Fish oil placebodietary